HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable

Journal of Immunology

Volumn 187, Issue 6, 2011, Pages 3391-3401

  De Rosa, Stephen C ^a,b,c   Thomas, Evan P ^b,c   Bui, John ^b   Huang, Yunda ^b,c   DeCamp, Allan ^b   Morgan, Cecilia ^b,c   Kalams, Spyros A ^d   Tomaras, Georgia D ^e   Akondy, Rama ^f   Ahmed, Rafi ^f   Lau, Chuen Yen ^g   Graham, Barney S ^g   Nabel, Gary J ^g   McElrath, M Juliana ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c HIV Vaccine Trials Network   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f EMORY UNIVERSITY   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; PLACEBO; PROTEIN ANTIBODY; RECOMBINANT ADENOVIRAL SEROTYPE 5 VACCINE; UNCLASSIFIED DRUG; VIRUS DNA;

ADENOVIRUS; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VIRUS RECOMBINANT;

ADENOVIRIDAE; ADOLESCENT; ADULT; AIDS VACCINES; ANTIBODIES, VIRAL; CELL SEPARATION; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENE PRODUCTS, POL; HIV; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; YOUNG ADULT;

EID: 80053078021     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101421     Document Type: Article

References (37)

1. Walker, B. D., and D. R. Burton. 2008. Toward an AIDS vaccine. Science 320: 760-764.
2. Cox, K. S., J. H. Clair, M. T. Prokop, K. J. Sykes, S. A. Dubey, J. W. Shiver, M. N. Robertson, and D. R. Casimiro. 2008. DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles. J. Virol. 82: 8161-8171.
3. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, et al Step Study Protocol Team. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-ofconcept trial. Lancet 372: 1881-1893.
4. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. De Souza, E. Adams, et al MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220.
5. Graham, B. S., R. A. Koup, M. Roederer, R. T. Bailer, M. E. Enama, Z. Moodie, J. E. Martin, M. M. McCluskey, B. K. Chakrabarti, L. Lamoreaux, et al Vaccine Research Center 004 Study Team. 2006. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis. 194: 1650-1660.
6. Catanzaro, A. T., R. A. Koup, M. Roederer, R. T. Bailer, M. E. Enama, Z. Moodie, L. Gu, J. E. Martin, L. Novik, B. K. Chakrabarti, et al Vaccine Research Center 006 Study Team. 2006. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replicationdefective recombinant adenovirus vector. J. Infect. Dis. 194: 1638-1649.
7. Peiperl, L., C. Morgan, Z. Moodie, H. Li, N. Russell, B. S. Graham, G. D. Tomaras, S. C. De Rosa, and M. J. McElrath; NIAID HIV Vaccine Trials Network. 2010. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS ONE 5: e13579.
8. Sprangers, M. C., W. Lakhai, W. Koudstaal, M. Verhoeven, B. F. Koel, R. Vogels, J. Goudsmit, M. J. Havenga, and S. Kostense. 2003. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 41: 5046-5052.
9. Bull, M., D. Lee, J. Stucky, Y. L. Chiu, A. Rubin, H. Horton, and M. J. McElrath. 2007. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J. Immunol. Methods 322: 57-69.
10. Li, F., U. Malhotra, P. B. Gilbert, N. R. Hawkins, A. C. Duerr, J. M. McElrath, L. Corey, and S. G. Self. 2006. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 24: 6893-6904.
11. Horton, H., E. P. Thomas, J. A. Stucky, I. Frank, Z. Moodie, Y. Huang, Y. L. Chiu, M. J. McElrath, and S. C. De Rosa. 2007. Optimization and validation of an 8- color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J. Immunol. Methods 323: 39-54.
12. Perfetto, S. P., P. K. Chattopadhyay, L. Lamoreaux, R. Nguyen, D. Ambrozak, R. A. Koup, and M. Roederer. 2006. Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. J. Immunol. Methods 313: 199-208.
13. McElrath, M. J., S. C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O. D. Defawe, D. K. Carter, J. Hural, R. Akondy, et al Step Study Protocol Team. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
14. Shulman, N., M. Bellew, G. Snelling, D. Carter, Y. Huang, H. Li, S. G. Self, M. J. McElrath, and S. C. De Rosa. 2008. Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials. Cytometry A 73: 847-856.
15. Goepfert, P. A., G. D. Tomaras, H. Horton, D. Montefiori, G. Ferrari, M. Deers, G. Voss, M. Koutsoukos, L. Pedneault, P. Vandepapeliere, et al NIAID HIV Vaccine Trials Network. 2007. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 25: 510-518.
16. Tomaras, G. D., N. L. Yates, P. Liu, L. Qin, G. G. Fouda, L. L. Chavez, A. C. Decamp, R. J. Parks, V. C. Ashley, J. T. Lucas, et al. 2008. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82: 12449-12463.
17. Holm, S. 1979. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6: 65-70.
18. Agresti, A., and B. A. Coull. 1998. Approximate is better than "exact" for interval estimation of binomial proportions. Am. Stat. 52: 119-126.
19. Betts, M. R., M. C. Nason, S. M. West, S. C. De Rosa, S. A. Migueles, J. Abraham, M. M. Lederman, J. M. Benito, P. A. Goepfert, M. Connors, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789.
20. Darrah, P. A., D. T. Patel, P. M. De Luca, R.W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13: 843-850.
21. Harari, A., C. Cellerai, F. B. Enders, J. Köstler, L. Codarri, G. Tapia, O. Boyman, E. Castro, S. Gaudieri, I. James, et al. 2007. Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc. Natl. Acad. Sci. USA 104: 16233-16238.
22. Precopio, M. L., M. R. Betts, J. Parrino, D. A. Price, E. Gostick, D. R. Ambrozak, T. E. Asher, D. C. Douek, A. Harari, G. Pantaleo, et al. 2007. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J. Exp. Med. 204: 1405-1416.
23. Sallusto, F., D. Lenig, R. Förster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
24. Brenchley, J. M., N. J. Karandikar, M. R. Betts, D. R. Ambrozak, B. J. Hill, L. E. Crotty, J. P. Casazza, J. Kuruppu, S. A. Migueles, M. Connors, et al. 2003. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101: 2711-2720.
25. Chattopadhyay, P. K., M. R. Betts, D. A. Price, E. Gostick, H. Horton, M. Roederer, and S. C. De Rosa. 2009. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J. Leukoc. Biol. 85: 88-97.
26. Giorgi, J. V., and R. Detels. 1989. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin. Immunol. Immunopathol. 52: 10-18.
27. Perreau, M., G. Pantaleo, and E. J. Kremer. 2008. Activation of a dendritic cell- T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J. Exp. Med. 205: 2717-2725.
28. Le Priol, Y., D. Puthier, C. Lécureuil, C. Combadière, P. Debré, C. Nguyen, and B. Combadière. 2006. High cytotoxic and specific migratory potencies of senescent CD8+ CD57+ cells in HIV-infected and uninfected individuals. J. Immunol. 177: 5145-5154.
29. Chong, L. K., R. J. Aicheler, S. Llewellyn-Lacey, P. Tomasec, P. Brennan, and E. C. Wang. 2008. Proliferation and interleukin 5 production by CD8hi CD57+ T cells. Eur. J. Immunol. 38: 995-1000.
30. Miller, J. D., R. G. Van der Most, R. S. Akondy, J. T. Glidewell, S. Albott, D. Masopust, K. Murali-Krishna, P. L. Mahar, S. Edupuganti, S. Lalor, et al. 2008. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
31. Catanzaro, A. T., M. Roederer, R. A. Koup, R. T. Bailer, M. E. Enama, M. C. Nason, J. E. Martin, S. Rucker, C. A. Andrews, P. L. Gomez, et al; VRC007 Study Team. 2007. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25: 4085-4092.
32. Kibuuka, H., R. Kimutai, L. Maboko, F. Sawe,M. S. Schunk, A. Kroidl, D. Shaffer, L. A. Eller, R. Kibaya, M. A. Eller, et al. 2010. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J. Infect. Dis. 201: 600-607.
33. Koup, R. A., L. Lamoreaux, D. Zarkowsky, R. T. Bailer, C. R. King, J. G. Gall, D. E. Brough, B. S. Graham, and M. Roederer. 2009. Replication-defective adenovirus vectors with multiple deletions do not induce measurable vectorspecific T cells in human trials. J. Virol. 83: 6318-6322.
34. Halwani, R., J. D. Boyer, B. Yassine-Diab, E. K. Haddad, T. M. Robinson, S. Kumar, R. Parkinson, L. Wu, M. K. Sidhu, R. Phillipson-Weiner, et al. 2008. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL- 12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J. Immunol. 180: 7969-7979.
35. Kutzler, M. A., T. M. Robinson, M. A. Chattergoon, D. K. Choo, A. Y. Choo, P. Y. Choe, M. P. Ramanathan, R. Parkinson, S. Kudchodkar, Y. Tamura, et al. 2005. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J. Immunol. 175: 112-123.
36. Sardesai, N. Y., and D. B. Weiner. 2011. Electroporation delivery of DNA vaccines: prospects for success. Curr. Opin. Immunol. 23: 421-429.
37. Vasan, S., A. Hurley, S. J. Schlesinger, D. Hannaman, D. F. Gardiner, D. P. Dugin, M. Boente-Carrera, R. Vittorino, M. Caskey, J. Andersen, et al. 2011. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS ONE 6: e19252.